Literature DB >> 29180377

Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.

David J T Campbell1, Braden J Manns1, Lesley J J Soril1, Fiona Clement1.   

Abstract

BACKGROUND: Research from 2006 documented substantial variation in medication coverage for residents across Canada. Since then, some provinces have implemented major medication plan reforms. We aimed to update the information on publicly funded medication insurance plans available across Canada and to compare out-of-pocket costs across the country.
METHODS: We compared provincial medication insurance plans using data from public websites and other public source documents. Using 2 hypothetical clinical examples, we determined the amount and type of a patient's out-of-pocket costs for 5 different patient subtypes that varied based on medication burden, age and income.
RESULTS: Each province offers a plan to all residents. Cost-sharing is employed across all provinces. Some residents must pay a premium to receive insurance or must pay 100% of their medication costs until they reach a deductible amount, above which government funding covers a portion of medication costs. With the scenario of low medication burden (medication cost about $500), out-of-pocket costs ranged from $250 to $2100 for higher-income residents and from $0 to $700 for lower-income residents. With the scenario of high medication burden (medication cost about $1800), the corresponding ranges were $250-$2500 and $0-$1100. The variation was due to province of residence, age and income.
INTERPRETATION: Variations in out-of-pocket payments continue to exist across the provinces, with some groups facing high expenses. Further work is required to understand the impact of different cost-sharing mechanisms, develop policies to limit out-of-pocket expenses and improve provincial drug plans. Copyright 2017, Joule Inc. or its licensors.

Entities:  

Year:  2017        PMID: 29180377      PMCID: PMC5741433          DOI: 10.9778/cmajo.20170065

Source DB:  PubMed          Journal:  CMAJ Open        ISSN: 2291-0026


  16 in total

1.  Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.

Authors:  Jamie R Daw; Steven G Morgan
Journal:  Health Policy       Date:  2011-10-05       Impact factor: 2.980

2.  Mandatory universal drug plan, access to health care and health: Evidence from Canada.

Authors:  Chao Wang; Qing Li; Arthur Sweetman; Jeremiah Hurley
Journal:  J Health Econ       Date:  2015-08-19       Impact factor: 3.883

3.  Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States.

Authors:  Marie-Pascale Pomey; Pierre-Gerlier Forest; Howard A Palley; Elisabeth Martin
Journal:  Milbank Q       Date:  2007-09       Impact factor: 4.911

4.  Estimated cost of universal public coverage of prescription drugs in Canada.

Authors:  Steven G Morgan; Michael Law; Jamie R Daw; Liza Abraham; Danielle Martin
Journal:  CMAJ       Date:  2015-03-16       Impact factor: 8.262

5.  Impact of high-deductible health plans on health care utilization and costs.

Authors:  Teresa M Waters; Cyril F Chang; William T Cecil; Panagiotis Kasteridis; David Mirvis
Journal:  Health Serv Res       Date:  2010-10-28       Impact factor: 3.402

Review 6.  Prescription drug insurance coverage and patient health outcomes: a systematic review.

Authors:  Aaron S Kesselheim; Krista F Huybrechts; Niteesh K Choudhry; Lisa A Fulchino; Danielle L Isaman; Mary K Kowal; Troyen A Brennan
Journal:  Am J Public Health       Date:  2015-02       Impact factor: 9.308

7.  Impact of a high-deductible health plan on outpatient visits and associated diagnostic tests.

Authors:  Sheila R Reddy; Dennis Ross-Degnan; Alan M Zaslavsky; Stephen B Soumerai; James F Wharam
Journal:  Med Care       Date:  2014-01       Impact factor: 2.983

Review 8.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

9.  What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.

Authors:  Marin C Gemmill; Sarah Thomson; Elias Mossialos
Journal:  Int J Equity Health       Date:  2008-05-02

Review 10.  Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review.

Authors:  Bikaramjit S Mann; Lianne Barnieh; Karen Tang; David J T Campbell; Fiona Clement; Brenda Hemmelgarn; Marcello Tonelli; Diane Lorenzetti; Braden J Manns
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more
  13 in total

1.  The impact of pharmaceutical rebates on patients' drug expenditures.

Authors:  K Ally Memedovich; Braden Manns; Reed Beall; Aidan Hollis; Fiona Clement
Journal:  CMAJ       Date:  2019-03-18       Impact factor: 8.262

2.  The human right to essential medicines applies to Canadians.

Authors:  Katrina Perehudoff; Nav Persaud; Lisa Forman
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

3.  Resident-Level Predictors of Dementia Pharmacotherapy at Long-Term Care Admission: The Impact of Different Drug Reimbursement Policies in Ontario and Saskatchewan: Prédicteurs de la pharmacothérapie de la démence au niveau des résidents lors de l'hospitalisation dans des soins de longue durée : l'impact de différentes politiques de remboursement des médicaments en Ontario et en Saskatchewan.

Authors:  Laura C Maclagan; Susan E Bronskill; Michael A Campitelli; Shenzhen Yao; Christoffer Dharma; David B Hogan; Nathan Herrmann; Joseph E Amuah; Colleen J Maxwell
Journal:  Can J Psychiatry       Date:  2020-04-10       Impact factor: 4.356

4.  Correction: Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.

Authors: 
Journal:  CMAJ Open       Date:  2018-01-03

5.  Drug coverage in Canada: gaps and opportunities.

Authors:  Fiona Clement; Katherine A Memedovich
Journal:  J Psychiatry Neurosci       Date:  2018-05       Impact factor: 6.186

6.  Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis.

Authors:  Mina Tadrous; Diana Martins; Muhammad M Mamdani; Tara Gomes
Journal:  CMAJ Open       Date:  2020-04-28

7.  Variation in Patient-Described Barriers to and Facilitators of Diabetes Management by Individual-Level Characteristics: A Cross-Sectional, Open-Ended Survey.

Authors:  David J T Campbell; Harleen Ghuttora; Ana Mladenovic; Jordan Smith; Ryan Leigh; Laura Desveaux; Noah Ivers; Braden Manns; Marcello Tonelli; Christopher Naugler; Brenda Hemmelgarn; Kerry A McBrien
Journal:  Clin Diabetes       Date:  2022

8.  Impact of brand drug discount cards on private insurer, government and patient expenditures.

Authors:  Michael R Law; Fiona K I Chan; Mark Harrison; Heather C Worthington
Journal:  CMAJ       Date:  2019-11-11       Impact factor: 8.262

9.  Exploring patient and pharmacist perspectives on complex interventions for cardiovascular prevention: A qualitative descriptive process evaluation.

Authors:  David J T Campbell; Terry Saunders-Smith; Braden J Manns; Marcello Tonelli; Noah Ivers; Brenda R Hemmelgarn; Ross T Tsuyuki; Raj Pannu; Kathryn King-Shier
Journal:  Health Expect       Date:  2020-10-13       Impact factor: 3.377

10.  Pharmacist and patient perspectives on recruitment strategies for randomized controlled trials: a qualitative analysis.

Authors:  Jane M Fletcher; Terry Saunders-Smith; Braden J Manns; Ross Tsuyuki; Brenda R Hemmelgarn; Marcello Tonelli; David J T Campbell
Journal:  BMC Med Res Methodol       Date:  2020-10-31       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.